Chemical composition and antifungal effect of Saccharomyces boulardii extract against Candida albicans clinical isolates

1. Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics -- Saccharomyces boulardii. Alimentary Pharmacology & Therapeutics 2007;26(6):767-78. 2. Buts JP, De Keyser N. Interaction of Saccharomyces boulardii with intestinal brush border membranes: key to probiotic effects? Journal of Pediatric Gastroenterology & Nutrition 2010; 51(4):532-3. 3. Calderone RA, Fonzi WA. Virulence factors of Candida albicans. Trends in Microbiology 2001;9(7):327-35. 4. L M, P B. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microbial Ecology in Health and Disease 1993; 6:157–71. 5. Zaouche A, Loukil C, De Lagausie P, Peuchmaur M, Macry J, Fitoussi F, et al. Effects of oral Saccharomyces boulardii on bacterial overgrowth, translocation, and intestinal adaptation after small-bowel resection in rats. Scandinavian Journal of Gastroenterology 2000;35(2):160-5. 6. Edwards-Ingram L, Gitsham P, Burton N, Warhurst G, Clarke I, Hoyle D, et al. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Applied and Environmental Microbiology 2007;73(8):2458-67. 7. J B, N dK. Effect of Saccharomyces boulardii on intestinal mucosa. Digestive Diseases and Sciences 2006;51:1485–92. 8. Berg R, Bernasconi P, Fowler D, Gautreaux M. Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. The Journal of Infectious Diseases 1993;168(5):1314-8. 9. Jawhara S, Poulain D. Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis. Medical Mycology 2007;45(8):691-700. 10. Krasowska A, Murzyn A, Dyjankiewicz A, Lukaszewicz M, Dziadkowiec D. The antagonistic effect of Saccharomyces boulardii on Candida albicans filamentation, adhesion and biofilm formation. FEMS Yeast Research 2009;9(8):1312-21. 11. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-; . The Clinical and Laboratory Standards Institute 2008a, 28 (2008). 12. Monteiro DR, Arias LS, Fernandes RA, Deszo da Silva LF, de Castilho M, da Rosa TO, et al. Antifungal activity of tyrosol and farnesol used in combination against Candida species in the planktonic state or forming biofilms. Journal of Applied Microbiology 2017;123(2):392-400. 13. Cordeiro Rde A, Teixeira CE, Brilhante RS, Castelo-Branco DS, Alencar LP, de Oliveira JS, et al. Exogenous tyrosol inhibits planktonic cells and biofilms of Candida species and enhances their susceptibility to antifungals. FEMS Yeast Research 2015;15(4):fov012. 14. MohammadSalehi R, Bayat M, Owlia P, Mousavi Gargari L, Hashemi J. Effect of Saccharomyces Boulardii Extract on SAP2 Gene Expression and Antifungal Susceptibility of Candida Albicans. Jundishapur Journal of Microbiology 2018;11(3). 15. Murzyn A, Krasowska A, Stefanowicz P, Dziadkowiec D, Lukaszewicz M. Capric acid secreted by S. boulardii inhibits C. albicans filamentous growth, adhesion and biofilm formation. PLoS One 2010;5(8):e12050. 16. Murzyn A, Krasowska A, Augustyniak D, Majkowska-Skrobek G, Lukaszewicz M, Dziadkowiec D. The effect of Saccharomyces boulardii on Candida albicans-infected human intestinal cell lines Caco-2 and Intestin 407. FEMS Microbiology Letters 2010;310(1):17-23.